Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing ...

The combination of Padcev and Keytruda showed promising clinical activity in UTUC patients, with a 25% ORR in primary lesions and 35% in target lesions. The study included 22 patients with intact ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...

The pre-filled syringes industry is growing at an exponential rate. With increasing demand for self-administration, a rise in biologics, large-volume delivery and the delayed EU MDR at the ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. The Keytruda-Lenvima regimen ...

Merck (NYSE:MRK) and Esai (OTCPK:ESALF) (OTCPK:ESAIY) announced Friday a mixed outcome in their Phase 3 LEAP-015 trial, which was designed to evaluate MRK’s anti-PD-1 therapy Keytruda and the Ja ...

SAE Media Group's 15th Annual Pre-Filled Syringes and Injectable Drug Devices Conference 2023 will be bigger than ever, with a pre-conference focus day exploring the advances in PFS design for ...

plus Keytruda (pembrolizumab) in patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). Also Read: Pfizer Q4 Earnings: Revenue And EPS Beat, Seagen And COVID ...

Enfortumab vedotin plus pembrolizumab cut the risk of death by 49% vs. chemo, with a median OS of 33.8 months vs. 15.9 months. The combination therapy reduced disease progression or death risk by ...

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028 ...

(RTTNews) - Merck (MRK) announced that Health Canada has granted approval for KEYTRUDA, Merck's anti-PD-1 therapy, as a treatment for adult patients with resectable Stage II, IIIA, or IIIB non ...